Table 6. Summary of Day 10 Recipient Cytokine Levels of Interest.
| Track 2 | Track 3 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyte pg/ml | Range | Median | IQR | Mean | SD | % Elevated* | Analyte pg/ml | Range | Median | IQR | Mean | SD | % Elevated* | P Value^ |
| EGF | 2.18–133.09 | 26.98 | 51.66 | 37.86 | 36.01 | 45.5 | EGF | <3.2–51.17 | 19.43 | 10.07 | 21.58 | 12.77 | 10.0 | 0.035 |
| IFNα2 | 4.83–60.70 | 12.49 | 22.95 | 19.19 | 17.09 | 9.1 | IFNα2 | 3.12–42.98 | 8.00 | 16.43 | 15.33 | 15.28 | 0.0 | 0.270 |
| IFNγ | <1.28–24.11 | 1.28 | 7.58 | 6.28 | 6.77 | 0.0 | IFNγ | <1.28–87.87 | 10.54 | 18.80 | 23.87 | 33.54 | 20.0 | 0.067 |
| IL-1RA | 4.41–3985.12 | 52.94 | 98.48 | 248.89 | 838.14 | 54.6 | IL-1RA | 28.06–308.19 | 66.91 | 50.22 | 88.29 | 82.57 | 70.0 | 0.190 |
| IL-3 | 0.10–2.03 | 1.28 | 0.00 | 1.10 | 0.48 | 4.6 | IL-3 | 0.37–1.28 | 1.28 | 0.46 | 1.05 | 0.38 | 0.0 | 0.380 |
| IL-6 | 0.32–1501.16 | 3.22 | 9.11 | 156.06 | 384.40 | 95.5 | IL-6 | 1.15–3377.42 | 57.86 | 832.13 | 743.11 | 1275.98 | 100.0 | 0.093 |
| IL-7 | 0.18–141.35 | 0.64 | 3.54 | 10.65 | 31.60 | 36.4 | IL-7 | <0.64–4.92 | 0.64 | 0.78 | 1.32 | 1.37 | 30.0 | 0.091 |
| IL-8 (CXCL8) | 2.0–158.35 | 5.82 | 7.55 | 18.41 | 35.31 | 95.5 | IL-8 (CXCL8) | 4.72–598.66 | 10.43 | 8.39 | 71.45 | 185.55 | 100.0 | 0.200 |
| IL-12p40 | 1.37–102.75 | 16.34 | 16.26 | 22.76 | 24.01 | 9.1 | IL-12p40 | 4.18–32.85 | 14.37 | 9.32 | 15.53 | 0.09 | 0.0 | 0.120 |
| IL-12p70 | 0.75–5.45 | 3.20 | 0.00 | 3.13 | 1.09 | 13.6 | IL-12p70 | 1.2–2.86 | 3.20 | 0.60 | 2.79 | 0.67 | 0.0 | 0.150 |
| IL-17A | 0.27–20.44 | 2.57 | 6.11 | 5.09 | 5.83 | 9.1 | IL-17A | 0.27–14.70 | 3.60 | 8.13 | 5.48 | 5.49 | 0.0 | 0.430 |
| IP-10 (CXCL10) | 84.38–24502.52 | 393.99 | 305.80 | 1863.33 | 5200.96 | 81.8 | IP-10 (CXCL10) | 223.02–2569.14 | 492.86 | 308.44 | 664.31 | 698.85 | 100.0 | 0.150 |
| MCP-1 (CCL2) | 158.37–2893.75 | 418.43 | 495.94 | 695.71 | 745.60 | 54.6 | MCP-1 (CCL2) | 182.03–3759.13 | 479.75 | 541.03 | 1064.89 | 1258.67 | 90.0 | 0.200 |
| MIP-1β (CCL4) | 22.83–218.53 | 39.91 | 13.87 | 54.87 | 46.93 | 81.8 | MIP-1β (CCL4) | 13.02–164.13 | 34.24 | 27.72 | 50.95 | 43.11 | 70.0 | 0.410 |
| RANTES (CCL5) | 1741.10–6677.48 | 2967.81 | 1648.37 | 3304.97 | 1257.30 | 9.1 | RANTES (CCL5) | 1788.05–5755.71 | 2752.26 | 782.41 | 2949.10 | 1112.64 | 10.0 | 0.215 |
| TNFα | 1.80–321.88 | 19.72 | 16.37 | 40.35 | 69.56 | 22.7 | TNFα | 14.44–145.46 | 26.09 | 42.83 | 46.81 | 45.19 | 30.0 | 0.380 |
| TNFβ | 2.20–11.00 | 3.06 | 1.98 | 4.02 | 2.47 | 9.1 | TNFβ | <2.56–14.35 | 4.98 | 7.56 | 7.00 | 4.80 | 40.0 | 0.045 |
| VEGF | <2.56–853.21 | 139.14 | 138.94 | 208.60 | 201.00 | 77.3 | VEGF | 8.02–664.70 | 151.71 | 273.96 | 249.70 | 226.80 | 90.0 | 0.320 |
| CRP ug/ml | 1.24–1357.70 | 20.21 | 80.35 | 116.05 | 286.54 | 72.7 | CRP ug/ml | 5.04–672.39 | 72.06 | 122.16 | 149.87 | 210.47 | 80.0 | 0.360 |
| NGAL ng/ml | 314.65–4192.62 | 1463.85 | 1712.12 | 1602.48 | 1147.21 | 86.4 | NGAL ng/ml | 575.42–6187.99 | 1175.22 | 1554.81 | 2073.92 | 1803.37 | 100.0 | 0.230 |
* The % of recipients with plasma values elevated above the normal control mean + 2xSD
^T-test was used to compare Means of Track 2 and Track 3; Statistically significant p values are highlighted in gray
SD, Standard Deviation of the Mean; IQR, Interquartile Range